http://www.biogenidec.com/

Burt Adleman, MD - Executive Vice President, Development:

Presentation on:

• Anti-CD80
• Anti-CD23
• Anti-LTbR
• Volociximab
• Anti-avb6
• Anti-BR3 mAb
• BAFF-Receptor Fc
• ADIFNb
• Anti-CRIPTO Toxin conjugated mAb
• Early Stage Programs

---

http://www.lilly.com/

Christopher Slapak, MD -  Medical Research Fellow (Executive Director), Cancer Research and Clinical Investigation
Richard Gaynor, MD - VP Cancer Research and Clinical Investigation

Presentation on:

• Enzastaurin Hydrochloride, orally active small-molecule inhibitor of protein kinase C (PKC) beta
• Survivin antisense oligonucleotide (ASO)
• TGF beta-receptor kinase inhibitors
• ASAP, a novel cytotoxic that induces apoptosis

---

http://www.kosan.com/

Robert Johnson, MD - Executive VP, Development

Presentation on:

• KOS-862 (Epothilone D) and KOS-1584, microtubule stabilizers
• KOS-953 (17-AAG) and KOS-1022 (DMAG), Hsp90 inhibitors
• KOS-1815, an inhibitor of CRM1 nuclear transport export processes
• KOS-2186, a novel MEK kinase pathway inhibitor

---

http://www.wyeth.com

Lee Allen, MD - Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area

Presentation on:

• Temsirolimus, an mTOR kinase inhibitor
• HKI-272, an irreversible pan-erB kinase inhibitor
• SKI-606, an orally active src kinase inhibitor
• MKI-833, an oral, reversible MEK kinase inhibitor
• CMC-544 and CMD-193, both monoclonal antibody targeted chemotherapy
• MST-997 and TTI-237, both microtubule inhibitors

---

http://en.sanofi-aventis.com/

Sunil Gupta, MD - Senior Director, Clinical Development Oncology

Presentation on:

• Tirapazimine
• XRP9881
• Xaliproden
• Alvocidib
• SR31747
• UVIDEM
• XRP6258
• SSR125329

---

http://www.gsk.com/

Peter Ho, MD - VP, Discovery Medicine - Oncology
Allen Oliff, MD -  Senior Vice President MMPD CEDD

Presentation on:

• Lapatinib, a dual erb-b kinase inhibitor
• GSK VEGF-R kinase inhibitor
• IL-18 cytokine for immunologically sensitive tumors
• TPO, an oral agent for thrombocytopenias
• NK-1 antagonist for emesis control
• Cathepsin-K inhibitor for metastasis control
• Pre-clinical pipeline of kinase targets and nucleoside analogs